Clinical trial · Interventional
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
Effect of Adding Electroacupuncture Combined With Standard Anti Chemotherapy-induced Peripheral Neuropathy Drugs to Anti-cancer Therapy-induced Peripheral Neuropathy: a Randomized Multicentered Clinical Trial.
NCT06858709CI-TRIAL-00088714recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to evaluate the potential benefits of using electroacupuncture to reduce the severity of chemotherapy-induced peripheral neuropathy for patients with peripheral neuropathy after chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chemotherapy-induced Peripheral Neuropathy (CIPN) | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment | Procedure | — | UNRESOLVED |
| True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment
- interventionNames
- Procedure: True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment
- type
- PLACEBO_COMPARATOR
- label
- Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment
- interventionNames
- Procedure: Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment
Primary outcomes (1)
- measure
- Difference of the CIPN grade from baseline to week 6 after baseline
- timeFrame
- From enrollment to week 6
- description
- The primary outcome will be the proportion of patients whose CIPN grade improved after the completion of 8 acupuncture treatments sessions.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older, of any nationality. * Patients diagnosed with malignant tumor. * Eligible patients will report altered sensations and/or pain and/or other neurological symptoms, with a grade between 2-3 for chemotherapy-induced peripheral neuropathy on the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events-version 5.0 (NCI-CTCAE.v-5.0). * Predicted life expectancy of ≥3 months. * Intact skin without any breaches or purulent discharge. * Written informed consent by the patient before enrolment Patients must be able to comply with the study protocol, which includes attending the treatment sessions on time and completing the study questionnaires in accordance with the study protocol. Exclusion Criteria: * History of pre-existing peripheral neuropathy before chemotherapy, including alcoholism, vitamin B deficiency, diabetes, HIV, congenital neuropathy, and toxic neuropathy. * Patients with skin damage, pus or scar at the acupuncture stimulation area. * Patients who are pregnant or breastfeeding. * Significant mental conditions. * Patients not fulfilling the inclusion criteria. * Patients receiving other acupuncture treatments during the trial.
References
Publications (0)
Data not yet available
No reference posted for this study.